Background Little is known about parental coronavirus disease 2019 (COVID-19) vaccine hesitancy in children with neurodevelopmental disorders (NDD). This survey estimated the prevalence and predictive factors of vaccine hesitancy among parents of children with NDD. Methods A nationally representative cross-sectional survey was conducted from October 10 to 31, 2021. A structured vaccine hesitancy questionnaire was used to collect data from parents aged ≥ 18 years with children with NDD. In addition, individual face-to-face interviews were conducted at randomly selected places throughout Bangladesh. Multiple logistic regression analysis was conducted to identify the predictors of vaccine hesitancy. Results A total of 396 parents participated in the study. Of these, 169 (42.7%) parents were hesitant to vaccinate their children. Higher odds of vaccine hesitancy were found among parents who lived in the northern zone (AOR = 17.15, 95% CI = 5.86–50.09; p < 0.001), those who thought vaccines would not be safe and effective for Bangladeshi children (AOR = 3.22, 95% CI = 1.68–15.19; p < 0.001), those who were either not vaccinated or did not receive the COVID-19 vaccine themselves (AOR = 12.14, 95% CI = 8.48–17.36; p < 0.001), those who said that they or their family members had not tested positive for COVID-19 (AOR = 2.13, 95% CI = 1.07–4.25), and those who did not lose a family member to COVID-19 (AOR = 2.12, 95% CI = 1.03–4.61; p = 0.040). Furthermore, parents who were not likely to believe that their children or a family member could be infected with COVID-19 the following year (AOR = 4.99, 95% CI = 1.81–13.77; p < 0.001) and who were not concerned at all about their children or a family member being infected the following year (AOR = 2.34, 95% CI = 1.65–8.37; p = 0.043) had significantly higher odds of COVID-19 vaccine hesitancy. Conclusions Given the high prevalence of vaccine hesitancy, policymakers, public health practitioners, and pediatricians can implement and support strategies to ensure that children with NDD and their caregivers and family members receive the COVID-19 vaccine to fight pandemic induced hazards.

No abstract

Abstract:A total of 58 patients of severe mitral stenosis with Wilkins score < 10 were studied, all of them underwent PTMC. Spirometry and peak expiratory flow rate were done before and after PTMC. A follow up echocardiographic assessment of successful PTMC and pulmonary artery systolic pressure were taken. Two patients died of PTMC related procedural complications.

Background: The deterioration in lung function in mitral stenosis correlates with the severity of stenotic valves. A correlation is noted between vital capacity and the severity of dyspnoea in patients with mitral stenosis. This study tried to evaluate the pattern of pulmonary function test in patient with severe mitral stenosis.Materials & Methods: This study involving 56 patients of severe mitral stenosis was performed in a referral cardiovascular center at Dhaka, Bangladesh from January to September, 2011. Colour doppler echocardiography and pulmonary function test were performed in each cases. Forced vital capacity (FVC), forced expiratory volume in first second (FEV1), FEV1/FVC and peak expiratory flow (PEF) rate was assessed from pulmonary function test. Finally, pattern of pulmonary function test in severe mitral stenosis was assessed.Results: Amomg 56 patients, 46 were female with a male female ratio 1: 0.22 and the mean age of patients was 28.76 ± 7.2. Among patients with severe mitral stenosis, mean FEV1 (%) was 60.18 ± 13.054. Minimum FVC (%) was 26, maximum was 90 with mean 53.80 ± 12.313. The PEF varied from 150 to 330 L/minute with mean 223.75 ± 62.3251. In current study, out of 56 patients, 2 cases had obstructive type and rest of the patients had restricted type of airway on pulmonary function.Conclusion: The brief results of this study reveal that severe mitral stenosis is associated with impaired pulmonary function, usually presenting restrictive airway pattern.Bangladesh Crit Care J September 2014; 2 (2): 57-59